Why Shares of Stoke Therapeutics Plummeted in September [The Motley Fool]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: The Motley Fool
Why Shares of Stoke Therapeutics Plummeted in September After top performance in August, the biotech was hit hard. Shares of Stoke Therapeutics ( NASDAQ:STOK ) crashed 42.6% in September, according to data provided by S&P Global Market Intelligence . That was a dramatic turnaround for the young biotech , which just had its IPO in June. August's story was dramatically different. Despite a lackluster quarterly earnings report mid-month, the share price soared 52% to end August at $37.44. Stoke's share price may have been a victim of its own success. According to its website, the company develops "medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney." Stoke hasn't released any news recently about the status of its products in development. However, numerous analysts initiated coverage of the company in July, when its share price was in the mid-$20s
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
STOK
Earnings
- 5/6/24 - Beat
STOK
Sec Filings
- 5/22/24 - Form 4
- 5/22/24 - Form 4
- 5/22/24 - Form 4
- STOK's page on the SEC website